A clinical study to evaluate the dosage, safety and efficacy of inhaled Cannabidiol

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Anxiety; Arthritis; Attention-deficit hyperactivity disorder; Depression; Insomnia; Pain
Focus Adverse reactions

09 Jun 2021 New trial record
02 Jun 2021 According to a Rapid Therapeutic Science Laboratories media release, the company has engaged Dr. Charles Powell, MD, (CMO, Founder) of a primary care group in North Texas with over 90,000 patients from which volunteers will be solicited for the planned studies. Dr. Powell will work in conjugation with Dr. Haresh Boghara, MD of Epic Medical Research (RTSL's primary medical investigator).
02 Jun 2021 According to a Rapid Therapeutic Science Laboratories media release, IND filing for metered dose inhaler (MDI) containing Cannabidiol (CBD) is expected in the next 30 days.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com